Broadcast Live   |   Upload & Publish  | About  | Register  | Sign in
E-mail:
Password:
Remember me on this computer
You need to install or upgrade your Flash Player!

3B NEXUS video platform & portal supports the latest version of Macromedia Flash player.


3B PLAYER by 3B NEXUS

Close [ X ]
Copy this code to embed & stream this video on your website
 
Copy this URL to share or create a link back to this video
Dr. Cord Dohrmann
Chief Science Officer
Germany
Evotec – Partner of choice for oncology drug discovery.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. The Company has established a unique position integrating leading technology platforms with substantial experience and expertise in key therapeutic areas including oncology to discover and develop highly differentiated therapeutics and superior biomarkers.

[ close ] 
Please select the appropriate option to comply with legal regulations

Individual Investor Professional Investor or Financial Advisor
This multimedia channel includes videos, webcasts and live broadcasts suitable for members of the general public over 18 years of age and not engaged in providing investment advice. Access this channel for personal interest & information only. This multimedia channel includes investor videos and webcast presentations, live broadcasts and documents intended only for authorised and regulated professionals and financial advisers eligible to provide investment advice to private investors.
I comply with these terms I comply with these terms
Remember my choice for all channels on this portal Enter Media Channel »
No reliance should be placed on the information on this site which may change without notice.
You should read the Terms & Conditions section before browsing this site.

Search in Sort By
1 2 3 4 of 4   MORE   SHOW
  Select a title or search in slides to skip chapters
00:00
Evotec, Dr. Cord Dohrmann, Evotec - Partner of choice for oncology drug discovery.
00:08
, Evotec at a glance
00:15
R&D;, Profitable, revenue, growth, alliances, pipeline, Phase III, Phase II and Phase I , Leader in high quality drug discovery solutions
01:18
scientists, location, Global reach for global projects - approx. 600 scientists
02:38
alliances, biology, Metabolics, Oncology, CNS, Immunology , Drug discovery alliances & more
03:08
value chain, cell types, chemistry, Best-in-class platforms yield superior productivity
04:03
pipeline, risk, Indication, Commercials , Deep clinical pipeline without financial risk
04:46
, Experience and current oncology partners
04:50
oncology platform, Targets, Tumor metabolism, compounds, Productive oncology platform
05:36
oncology alliances, Drug discovery partners, Biomarker development , Current oncology alliances
07:20
, Examples of cancer alliances
07:25
Boehringer Ingelheim-Alliance, oncology, Milestones , Boehringer Ingelheim-Alliance Focus on cancer
08:10
Biomarkers , Response Prediction, Personalized Medicine, chemotherapy, Targeted Therapies , The future paradigm in oncology
08:50
Phospho-signatures as biomarkers, proteins, pathways, phosphorylation , Phospho-signatures as biomarkers
09:40
oncology, biomarker development, PhosphoScout, quantification of cellular phosphorylation , Roche oncology alliance
10:06
, Opportunities with Evotec
10:10
Opportunities, Drug Design platforms, Mesoscale, acetylomics, Phenotypic, Epigenetic , Leveraging Evotec expertise in oncology
10:38
, Evotec - contact info